S&P 500   4,209.66 (+2.11%)
DOW   33,298.75 (+1.60%)
QQQ   325.49 (+2.65%)
AAPL   168.86 (+2.39%)
MSFT   288.59 (+2.23%)
META   178.02 (+5.63%)
GOOGL   119.72 (+2.65%)
AMZN   142.68 (+3.52%)
TSLA   882.45 (+3.82%)
NVDA   181.03 (+5.95%)
NIO   19.99 (+4.28%)
BABA   92.59 (+1.54%)
AMD   99.04 (+3.66%)
MU   61.44 (+3.87%)
T   18.05 (-0.28%)
CGC   3.32 (+15.68%)
GE   77.35 (+3.23%)
F   15.45 (+1.71%)
DIS   112.13 (+3.70%)
AMC   23.29 (+3.74%)
PYPL   98.30 (+4.04%)
PFE   49.85 (+0.14%)
NFLX   243.64 (+5.96%)
S&P 500   4,209.66 (+2.11%)
DOW   33,298.75 (+1.60%)
QQQ   325.49 (+2.65%)
AAPL   168.86 (+2.39%)
MSFT   288.59 (+2.23%)
META   178.02 (+5.63%)
GOOGL   119.72 (+2.65%)
AMZN   142.68 (+3.52%)
TSLA   882.45 (+3.82%)
NVDA   181.03 (+5.95%)
NIO   19.99 (+4.28%)
BABA   92.59 (+1.54%)
AMD   99.04 (+3.66%)
MU   61.44 (+3.87%)
T   18.05 (-0.28%)
CGC   3.32 (+15.68%)
GE   77.35 (+3.23%)
F   15.45 (+1.71%)
DIS   112.13 (+3.70%)
AMC   23.29 (+3.74%)
PYPL   98.30 (+4.04%)
PFE   49.85 (+0.14%)
NFLX   243.64 (+5.96%)
S&P 500   4,209.66 (+2.11%)
DOW   33,298.75 (+1.60%)
QQQ   325.49 (+2.65%)
AAPL   168.86 (+2.39%)
MSFT   288.59 (+2.23%)
META   178.02 (+5.63%)
GOOGL   119.72 (+2.65%)
AMZN   142.68 (+3.52%)
TSLA   882.45 (+3.82%)
NVDA   181.03 (+5.95%)
NIO   19.99 (+4.28%)
BABA   92.59 (+1.54%)
AMD   99.04 (+3.66%)
MU   61.44 (+3.87%)
T   18.05 (-0.28%)
CGC   3.32 (+15.68%)
GE   77.35 (+3.23%)
F   15.45 (+1.71%)
DIS   112.13 (+3.70%)
AMC   23.29 (+3.74%)
PYPL   98.30 (+4.04%)
PFE   49.85 (+0.14%)
NFLX   243.64 (+5.96%)
S&P 500   4,209.66 (+2.11%)
DOW   33,298.75 (+1.60%)
QQQ   325.49 (+2.65%)
AAPL   168.86 (+2.39%)
MSFT   288.59 (+2.23%)
META   178.02 (+5.63%)
GOOGL   119.72 (+2.65%)
AMZN   142.68 (+3.52%)
TSLA   882.45 (+3.82%)
NVDA   181.03 (+5.95%)
NIO   19.99 (+4.28%)
BABA   92.59 (+1.54%)
AMD   99.04 (+3.66%)
MU   61.44 (+3.87%)
T   18.05 (-0.28%)
CGC   3.32 (+15.68%)
GE   77.35 (+3.23%)
F   15.45 (+1.71%)
DIS   112.13 (+3.70%)
AMC   23.29 (+3.74%)
PYPL   98.30 (+4.04%)
PFE   49.85 (+0.14%)
NFLX   243.64 (+5.96%)
NASDAQ:VERU

Veru - VERU Stock Forecast, Price & News

$11.72
+0.22 (+1.91%)
(As of 08/10/2022 03:29 PM ET)
Add
Compare
Today's Range
$11.34
$11.88
50-Day Range
$11.20
$17.23
52-Week Range
$4.34
$18.40
Volume
150,327 shs
Average Volume
12.61 million shs
Market Capitalization
$938.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.40

Veru MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
206.5% Upside
$35.40 Price Target
Short Interest
Healthy
30.07% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.25mentions of Veru in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.58) to ($0.51) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.12 out of 5 stars

Medical Sector

582nd out of 1,108 stocks

Pharmaceutical Preparations Industry

289th out of 542 stocks

VERU stock logo

About Veru (NASDAQ:VERU) Stock

Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.

Veru Trading Down 4.6 %

Shares of VERU opened at $11.50 on Wednesday. Veru has a 12 month low of $4.34 and a 12 month high of $18.40. The stock's 50 day moving average is $13.34 and its two-hundred day moving average is $9.85. The firm has a market cap of $920.85 million, a P/E ratio of -33.82 and a beta of -0.40.

Veru (NASDAQ:VERU - Get Rating) last released its earnings results on Thursday, May 12th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.02). The firm had revenue of $13.03 million during the quarter, compared to analysts' expectations of $15.18 million. Veru had a negative net margin of 45.56% and a negative return on equity of 18.64%. During the same quarter last year, the business earned ($0.04) EPS. Equities research analysts forecast that Veru will post -0.58 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on VERU. HC Wainwright upped their price objective on Veru from $21.00 to $24.00 and gave the stock a "buy" rating in a research note on Tuesday, April 12th. Jefferies Financial Group upped their price objective on Veru from $33.00 to $55.00 in a research note on Friday, May 13th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Veru in a research note on Friday, May 13th. Brookline Capital Acquisition raised their target price on Veru from $29.00 to $31.00 and gave the stock a "buy" rating in a report on Wednesday, May 18th. Finally, TheStreet raised Veru from a "d+" rating to a "c" rating in a report on Friday, April 29th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Veru has a consensus rating of "Buy" and a consensus price target of $35.40.

Receive VERU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veru and its competitors with MarketBeat's FREE daily newsletter.

VERU Stock News Headlines

Veru Target of Unusually High Options Trading (NASDAQ:VERU)
See More Headlines
Receive VERU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Veru and its competitors with MarketBeat's FREE daily newsletter.

VERU Company Calendar

Last Earnings
5/12/2022
Today
8/10/2022
Next Earnings (Confirmed)
8/11/2022
Fiscal Year End
9/30/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Personal Products
Sector
Medical
Current Symbol
NASDAQ:VERU
CUSIP
31446210
Employees
252
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$35.40
High Stock Price Forecast
$55.00
Low Stock Price Forecast
$24.00
Forecasted Upside/Downside
+202.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$7.39 million
Pretax Margin
-50.75%

Debt

Sales & Book Value

Annual Sales
$61.26 million
Book Value
$1.91 per share

Miscellaneous

Free Float
61,577,000
Market Cap
$938.47 million
Optionable
Optionable
Beta
-0.40

Key Executives

  • Dr. Mitchell S. Steiner F.A.C.S (Age 61)
    F.A.C.S., M.D., Chairman, Pres & CEO
    Comp: $1.43M
  • Dr. Harry Fisch F.A.C.S. (Age 63)
    M.D., Vice Chairman & Chief Corp. Officer
    Comp: $648.12k
  • Ms. Michele Greco (Age 63)
    CFO & Chief Admin. Officer
    Comp: $659.62k
  • Dr. K. Gary Barnette Ph.D. (Age 54)
    Chief Scientific Officer
    Comp: $636.7k
  • Mr. Samuel Fisch
    Exec. Director of Investor Relations & Corp. Communications
  • Mr. Michael J. Purvis
    Exec. VP, Gen. Counsel & Corp. Strategy and Sec.
  • Mr. Kevin J. Gilbert CPA
    J.D., Exec. VP of Corp. Devel.
  • Mr. Phillip Kuhn
    Exec. VP of Strategy & Commercial
  • Dr. Domingo Rodriguez (Age 60)
    Exec. VP of Clinical Operations
  • Mr. Gary Bird Ph.D.
    Sr. VP of Quality Oversight













VERU Stock - Frequently Asked Questions

Should I buy or sell Veru stock right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Veru in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VERU shares.
View VERU analyst ratings
or view top-rated stocks.

What is Veru's stock price forecast for 2022?

5 Wall Street research analysts have issued 1-year target prices for Veru's stock. Their VERU share price forecasts range from $24.00 to $55.00. On average, they anticipate the company's share price to reach $35.40 in the next twelve months. This suggests a possible upside of 203.6% from the stock's current price.
View analysts price targets for VERU
or view top-rated stocks among Wall Street analysts.

How have VERU shares performed in 2022?

Veru's stock was trading at $5.89 at the beginning of the year. Since then, VERU stock has increased by 98.0% and is now trading at $11.66.
View the best growth stocks for 2022 here
.

When is Veru's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our VERU earnings forecast
.

How can I listen to Veru's earnings call?

Veru will be holding an earnings conference call on Thursday, August 11th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 412-317-0088 with passcode "1902173".

How were Veru's earnings last quarter?

Veru Inc. (NASDAQ:VERU) announced its earnings results on Thursday, May, 12th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.16) by $0.02. The firm had revenue of $13.03 million for the quarter, compared to analyst estimates of $15.18 million. Veru had a negative trailing twelve-month return on equity of 18.64% and a negative net margin of 45.56%. During the same period in the prior year, the business posted ($0.04) earnings per share.

What other stocks do shareholders of Veru own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Veru investors own include Kadmon (KDMN), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Corbus Pharmaceuticals (CRBP), Matinas BioPharma (MTNB), OrganiGram (OGI), Vaxart (VXRT), Rigel Pharmaceuticals (RIGL), SCYNEXIS (SCYX) and VBI Vaccines (VBIV).

What is Veru's stock symbol?

Veru trades on the NASDAQ under the ticker symbol "VERU."

Who are Veru's major shareholders?

Veru's stock is owned by a variety of institutional and retail investors. Top institutional investors include Silverarc Capital Management LLC (0.00%), Level Four Advisory Services LLC (0.12%), Belvedere Trading LLC (0.00%), Ignite Planners LLC (0.06%), Segment Wealth Management LLC (0.04%) and Private Advisor Group LLC (0.03%). Insiders that own company stock include Harry Fisch, Jesus Socorro, K Gary Barnette, Lucy Lu, Michele Greco and Mitchell Shuster Steiner.
View institutional ownership trends
.

How do I buy shares of Veru?

Shares of VERU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Veru's stock price today?

One share of VERU stock can currently be purchased for approximately $11.66.

How much money does Veru make?

Veru (NASDAQ:VERU) has a market capitalization of $933.66 million and generates $61.26 million in revenue each year. The company earns $7.39 million in net income (profit) each year or ($0.34) on an earnings per share basis.

How many employees does Veru have?

The company employs 252 workers across the globe.

How can I contact Veru?

Veru's mailing address is 48 NW 25th Street Suite 102, Miami FL, 33127. The official website for the company is www.veruhealthcare.com. The company can be reached via phone at (305) 509-6897, via email at veruinvestor@verupharma.com, or via fax at 312-595-9122.

This page (NASDAQ:VERU) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.